Thompson Christopher F, Quraishi Nazia, Ali Amjad, Mosley Ralph T, Tata James R, Hammond Milton L, Balkovec James M, Einstein Monica, Ge Lan, Harris Georgianna, Kelly Terri M, Mazur Paul, Pandit Shilpa, Santoro Joseph, Sitlani Ayesha, Wang Chuanlin, Williamson Joanne, Miller Douglas K, Yamin Ting-Ting D, Thompson Chris M, O'Neill Edward A, Zaller Dennis, Forrest Michael J, Carballo-Jane Ester, Luell Silvi
Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA.
Bioorg Med Chem Lett. 2007 Jun 15;17(12):3354-61. doi: 10.1016/j.bmcl.2007.03.103. Epub 2007 Apr 5.
Chemistry was developed to synthesize the title series of compounds. The ability of these novel ligands to bind to the glucocorticoid receptor was investigated. These compounds were also tested in a series of functional assays and some were found to display the profile of a dissociated glucocorticoid. The SAR of the 6,5-bicyclic series differed markedly from the previously reported 6,6-series. Molecular modeling studies were employed to understand the conformational differences between the two series of compounds, which may explain their divergent activity. Two compounds were profiled in vivo and shown to reduce inflammation in a mouse model. An active metabolite is suspected in one case.